BRAF and melanoma: Of patients with stage III/IV BRAF-mutated melanoma, 20% (n = 372/1896) received immunotherapy only, 31% (n = 583/1896) received targeted therapy only, 20% (n = 383/1896) received immunotherapy and targeted therapy, and 29% (n = 558/1896) received neither immunotherapy nor targeted therapy (Table S9; see Supporting Information).